TuisAPN • JSE
add
Aspen Pharmacare Holdings Ltd
Vorige sluiting
ZACÂ 15Â 739,00
Dagwisseling
ZACÂ 15Â 610,00 - ZACÂ 16Â 449,00
Jaarwisseling
ZACÂ 14Â 141,00 - ZACÂ 25Â 296,00
Markkapitalisasie
73,03Â mjd ZAR
Gemiddelde volume
1,72Â m
P/V-verhouding
16,23
Dividend-opbrengs
2,19%
PrimĂŞre beurs
JSE
In die nuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
(ZAR) | Des. 2024info | J/J-verandering |
---|---|---|
Inkomste | 10,98Â mjd | 3,87% |
Bedryfskoste | 3,28Â mjd | 12,84% |
Netto inkomste | 1,19Â mjd | 3,20% |
Netto winsgrens | 10,87 | -0,73% |
Wins per aandeel | — | — |
EBITDA | 2,47Â mjd | 11,05% |
Effektiewe belastingkoers | 25,02% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
(ZAR) | Des. 2024info | J/J-verandering |
---|---|---|
Kontant en korttermynbeleggings | 6,80Â mjd | -41,33% |
Totale bates | 136,60Â mjd | -1,93% |
Totale aanspreeklikheid | 51,51Â mjd | -4,06% |
Totale ekwiteit | 85,09 mjd | — |
Uitstaande aandele | 444,10 m | — |
Prys om te bespreek | 0,82 | — |
Opbrengs op bates | 3,56% | — |
Opbrengs op kapitaal | 4,04% | — |
Kontantvloei
Netto kontantverandering
(ZAR) | Des. 2024info | J/J-verandering |
---|---|---|
Netto inkomste | 1,19Â mjd | 3,20% |
Kontant van bedrywe | 902,50Â m | -26,57% |
Kontant van beleggings | -1,40Â mjd | 54,76% |
Kontant van finansiering | 479,50Â m | -75,45% |
Netto kontantverandering | -208,00Â m | -427,56% |
Beskikbare kontantvloei | 155,00Â m | 185,99% |
Meer oor
Aspen Pharmacare Holdings Limited is a public multinational pharmaceutical company headquartered in uMhlanga, South Africa. Founded in 1997, it listed on the Johannesburg Stock Exchange in 1998, and purchased South African Druggists in 1999 before expanding into international markets. Currently the largest pharmaceutical company in Africa through aggressive mergers and expansion, with major manufacturing sites in locations such as Gqeberha in South Africa, Bad Oldesloe in Germany, Notre-Dame-de-Bondeville in France, and Oss, Netherlands, Aspen is known for manufacturing and distributing branded pharmaceuticals as well as generic HIV/AIDS antiretrovirals and cancer medications. Among other products, Aspen has also been involved in manufacturing the Janssen COVID-19 vaccine through "fill and finish", and has the rights to sell the product under its own brand name Aspenovax. The company's revenue in 2022 was R38.6 billion. In 2016 Aspen was fined for high prices on cancer drugs, and after an investigation Aspen committed to reduce prices for 5 years in the European Union. Wikipedia
HUB
Gestig
1850
Hoofkwartier
Webwerf
Werknemers
9Â 109